{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:06:45Z","timestamp":1777054005862,"version":"3.51.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12026-017-8931-1","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T12:24:49Z","timestamp":1498652689000},"page":"798-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":182,"title":["Dendritic cell-based immunotherapy: a basic review and recent advances"],"prefix":"10.1007","volume":"65","author":[{"given":"Jo\u00e3o","family":"Constantino","sequence":"first","affiliation":[]},{"given":"C\u00e9lia","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Bruno Miguel","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Maria Teresa","family":"Cruz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"8931_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265\u201377.","journal-title":"Nat Rev Cancer"},{"key":"8931_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245\u201352.","journal-title":"Nature"},{"key":"8931_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/690643","volume":"2012","author":"I Van Brussel","year":"2012","unstructured":"Van Brussel I, Berneman ZN, Cools N. Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system. Mediat Inflamm. 2012;2012:1\u201314.","journal-title":"Mediat Inflamm"},{"key":"8931_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419\u201326.","journal-title":"Nature"},{"key":"8931_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2009.09.067","volume":"625","author":"H Borghaei","year":"2009","unstructured":"Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625:41\u201354.","journal-title":"Eur J Pharmacol"},{"key":"8931_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/mt.2011.57","volume":"19","author":"JE Boudreau","year":"2011","unstructured":"Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther. 2011;19:841\u201353.","journal-title":"Mol Ther"},{"key":"8931_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12:557\u201369.","journal-title":"Nat Rev Immunol"},{"key":"8931_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","volume":"19","author":"P Blanco","year":"2008","unstructured":"Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41\u201352.","journal-title":"Cytokine Growth Factor Rev"},{"key":"8931_CR9","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/onc.2008.267","volume":"27","author":"I Waldhauer","year":"2008","unstructured":"Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27:5932\u201343.","journal-title":"Oncogene"},{"key":"8931_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14:135\u201346.","journal-title":"Nat Rev Cancer"},{"key":"8931_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331:1565\u201370.","journal-title":"Science"},{"key":"8931_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006;6:715\u201327.","journal-title":"Nat. Rev. Immunol."},{"key":"8931_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","volume":"168","author":"J Constantino","year":"2016","unstructured":"Constantino J, Gomes C, Falc\u00e3o A, Cruz MT, Neves BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res. 2016;168:74\u201395.","journal-title":"Transl Res"},{"key":"8931_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/imt.09.43","volume":"2","author":"RL Sabado","year":"2010","unstructured":"Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy. 2010;2:37\u201356.","journal-title":"Immunotherapy"},{"key":"8931_CR15","doi-asserted-by":"crossref","unstructured":"Amedei A, Benagiano M, Della Bella C, Niccolai E, D\u2019Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol. 2011;2011","DOI":"10.1155\/2011\/437348"},{"key":"8931_CR16","doi-asserted-by":"crossref","unstructured":"Nicolette CA, et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine. 2007;25","DOI":"10.1016\/j.vaccine.2007.06.006"},{"key":"8931_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1251\/bpo62","volume":"5","author":"B Obermaier","year":"2003","unstructured":"Obermaier B, et al. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online. 2003;5:197\u2013203.","journal-title":"Biol Proced Online"},{"key":"8931_CR18","first-page":"6451","volume":"61","author":"J Banchereau","year":"2001","unstructured":"Banchereau J, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451\u20138.","journal-title":"Cancer Res"},{"key":"8931_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.humimm.2009.02.004","volume":"70","author":"E Klechevsky","year":"2009","unstructured":"Klechevsky E, et al. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum Immunol. 2009;70:281\u20138.","journal-title":"Hum Immunol"},{"key":"8931_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.4049\/jimmunol.165.1.566","volume":"165","author":"B Pulendran","year":"2000","unstructured":"Pulendran B, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol. 2000;165:566\u201372.","journal-title":"J Immunol"},{"key":"8931_CR21","first-page":"97","volume":"109","author":"D O\u2019Neill","year":"2005","unstructured":"O\u2019Neill D, Bhardwaj N. Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol Med. 2005;109:97\u2013112.","journal-title":"Methods Mol Med"},{"key":"8931_CR22","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood-2004-08-3105","volume":"105","author":"M Schnurr","year":"2005","unstructured":"Schnurr M, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood. 2005;105:2465\u201372.","journal-title":"Blood"},{"key":"8931_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1006\/mthe.2000.0027","volume":"1","author":"R Schroers","year":"2000","unstructured":"Schroers R, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 2000;1:171\u20139.","journal-title":"Mol Ther"},{"key":"8931_CR24","doi-asserted-by":"crossref","unstructured":"Dyall J, Latouche JB, Schnell S, Sadelain M. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood. 2001;97:114\u201321.","DOI":"10.1182\/blood.V97.1.114"},{"key":"8931_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/104303404322959542","volume":"15","author":"G Liz\u00e9e","year":"2004","unstructured":"Liz\u00e9e G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Ther. 2004;15:393\u2013404.","journal-title":"Hum Gene Ther"},{"key":"8931_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt1390","volume":"26","author":"L Yang","year":"2008","unstructured":"Yang L, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol. 2008;26:326\u201334.","journal-title":"Nat Biotechnol"},{"key":"8931_CR27","doi-asserted-by":"crossref","unstructured":"Nair SK, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002;235","DOI":"10.1097\/00000658-200204000-00013"},{"key":"8931_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.0105-2896.2004.00139.x","volume":"199","author":"E Gilboa","year":"2004","unstructured":"Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004;199:251\u201363.","journal-title":"Immunol Rev"},{"key":"8931_CR29","first-page":"3388","volume":"61","author":"A Heiser","year":"2001","unstructured":"Heiser A, et al. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001;61:3388\u201393.","journal-title":"Cancer Res"},{"key":"8931_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3858\/emm.2009.41.2.008","volume":"41","author":"K Shortman","year":"2009","unstructured":"Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med. 2009;41:61\u20136.","journal-title":"Exp Mol Med"},{"key":"8931_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.imbio.2006.05.021","volume":"211","author":"PJ Tacken","year":"2006","unstructured":"Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology. 2006;211:599\u2013608.","journal-title":"Immunobiology"},{"key":"8931_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.smim.2011.01.004","volume":"23","author":"H Ueno","year":"2011","unstructured":"Ueno H, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol. 2011;23:21\u20137.","journal-title":"Semin Immunol"},{"key":"8931_CR33","doi-asserted-by":"crossref","unstructured":"Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic cells in vivo for cancer therapy. Front Immunol. 2012;3","DOI":"10.3389\/fimmu.2012.00013"},{"key":"8931_CR34","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4161\/onci.21494","volume":"1","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012;1:1111\u201334.","journal-title":"Oncoimmunology"},{"key":"8931_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fimmu.2013.00454","volume":"4","author":"L Butterfield","year":"2013","unstructured":"Butterfield L, Dendritic H. Cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol. 2013;4:454.","journal-title":"Front Immunol"},{"key":"8931_CR36","doi-asserted-by":"crossref","unstructured":"L\u00f3pez MN, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol. 2009;27","DOI":"10.1200\/JCO.2008.18.0794"},{"key":"8931_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"FJ Hsu","year":"1996","unstructured":"Hsu FJ, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52\u20138.","journal-title":"Nat Med"},{"key":"8931_CR38","doi-asserted-by":"crossref","unstructured":"Benteyn D, et al. Characterization of CD 8 + T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013","DOI":"10.1155\/2013\/976383"},{"key":"8931_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","volume":"117","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt J, et al. Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011;117:393\u2013402.","journal-title":"Blood"},{"key":"8931_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-3-9","volume":"3","author":"MA Morse","year":"2005","unstructured":"Morse MA, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9.","journal-title":"J Transl Med"},{"key":"8931_CR41","doi-asserted-by":"crossref","unstructured":"Dhodapkar, M. V et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 6, 232ra51 (2014).","DOI":"10.1126\/scitranslmed.3008068"},{"key":"8931_CR42","doi-asserted-by":"crossref","unstructured":"Yi HD, Appel S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand J Immunol. (2013);78:167\u201371.","DOI":"10.1111\/sji.12060"},{"key":"8931_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.imlet.2013.09.021","volume":"155","author":"I Bonaccorsi","year":"2013","unstructured":"Bonaccorsi I, Pezzino G, Morandi B, Ferlazzo G. Novel perspectives on dendritic cell-based immunotherapy of cancer. Immunol Lett. 2013;155:6\u201310.","journal-title":"Immunol Lett"},{"key":"8931_CR44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747\u201352.","journal-title":"Nat Med"},{"key":"8931_CR45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita H, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482:400\u20134.","journal-title":"Nature"},{"key":"8931_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3109\/14653240903446902","volume":"12","author":"BM Helfer","year":"2010","unstructured":"Helfer BM, et al. Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy. 2010;12:238\u201350.","journal-title":"Cytotherapy"},{"key":"8931_CR47","first-page":"779","volume":"138","author":"T Mohan","year":"2013","unstructured":"Mohan T, Verma P, Nageswara Rao D. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138:779\u201395.","journal-title":"Indian J Med Res"},{"key":"8931_CR48","doi-asserted-by":"crossref","unstructured":"Adams S, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol. 2008;181","DOI":"10.4049\/jimmunol.181.1.776"},{"key":"8931_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-065X.2009.00765.x","volume":"229","author":"C Wang","year":"2009","unstructured":"Wang C, Lin GHY, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev. 2009;229:192\u2013215.","journal-title":"Immunol Rev"},{"key":"8931_CR50","first-page":"3459","volume":"62","author":"KF May","year":"2002","unstructured":"May KF, Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 2002;62:3459\u201365.","journal-title":"Cancer Res"},{"key":"8931_CR51","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1002\/eji.200838958","volume":"39","author":"O Murillo","year":"2009","unstructured":"Murillo O, et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol. 2009;39:2424\u201336.","journal-title":"Eur J Immunol"},{"key":"8931_CR52","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2009;229:152\u201372.","journal-title":"Immunol Rev"},{"key":"8931_CR53","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nm1183","volume":"11","author":"BA Hanks","year":"2005","unstructured":"Hanks BA, et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med. 2005;11:130\u20137.","journal-title":"Nat Med"},{"key":"8931_CR54","doi-asserted-by":"crossref","unstructured":"Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomed Nanotechnol Biol Med. (2010);6:523\u20139.","DOI":"10.1016\/j.nano.2010.01.001"},{"key":"8931_CR55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1084\/jem.20051639","volume":"203","author":"SB Boscardin","year":"2006","unstructured":"Boscardin SB, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med. 2006;203:599\u2013606.","journal-title":"J Exp Med"},{"key":"8931_CR56","doi-asserted-by":"crossref","unstructured":"Zhou F, Li X, Naylor MF, Hode T, Nordquist RE, Alleruzzo L, Raker J, Lam SS, Du N, Shi L, Wang X, C. W. InCVAX-A novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett 359(2), 169\u2013177 (2015).","DOI":"10.1016\/j.canlet.2015.01.029"},{"key":"8931_CR57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231\u20137.","journal-title":"Curr Opin Immunol"},{"key":"8931_CR58","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<808::AID-IJC23>3.0.CO;2-J","volume":"81","author":"WR Chen","year":"1999","unstructured":"Chen WR, Zhu WG, Dynlacht JR, Liu H, Nordquist RE. Long-term tumor resistance induced by laser photo-immunotherapy. Int J Cancer. 1999;81:808\u201312.","journal-title":"Int J Cancer"},{"key":"8931_CR59","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1039\/c0pp00306a","volume":"10","author":"X Li","year":"2011","unstructured":"Li X, et al. Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients. Photochem Photobiol Sci. 2011;10:817\u201321.","journal-title":"Photochem Photobiol Sci"},{"key":"8931_CR60","doi-asserted-by":"crossref","unstructured":"Graziela Romagnoli, Bruna Zelante, Patr\u00edcia Toniolo, I. M. and & Barbuto, J. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front Immunol 5, (2015).","DOI":"10.3389\/fimmu.2014.00692"},{"key":"8931_CR61","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3390\/cancers3022223","volume":"3","author":"K Hasumi","year":"2011","unstructured":"Hasumi K, Aoki Y, Watanabe R, Hankey KG, Mann DL. Therapeutic response in patients with advanced malignancies treated with combined dendritic cell\u2013activated T cell based immunotherapy and intensity\u2013modulated radiotherapy. Cancers (Basel). 2011;3:2223\u201342.","journal-title":"Cancers (Basel)"},{"key":"8931_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cellimm.2010.03.001","volume":"263","author":"LW Pfannenstiel","year":"2010","unstructured":"Pfannenstiel LW, Lam SSK, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010;263:79\u201387.","journal-title":"Cell Immunol"},{"key":"8931_CR63","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-009-0734-3","volume":"59","author":"V Radojcic","year":"2010","unstructured":"Radojcic V, et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010;59:137\u201348.","journal-title":"Cancer Immunol Immunother"},{"key":"8931_CR64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00262-012-1334-1","volume":"62","author":"W Hobo","year":"2013","unstructured":"Hobo W, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother. 2013;62:285\u201397.","journal-title":"Cancer Immunol Immunother"},{"key":"8931_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1172\/JCI26169","volume":"116","author":"K Evel-Kabler","year":"2006","unstructured":"Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells\u2019 ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest. 2006;116:90\u2013100.","journal-title":"J Clin Invest"},{"key":"8931_CR66","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2005-07-2760","volume":"107","author":"N Cohen","year":"2006","unstructured":"Cohen N, et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood. 2006;107:2037\u201344.","journal-title":"Blood"},{"key":"8931_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2002-02-0538","volume":"101","author":"D Berrebi","year":"2003","unstructured":"Berrebi D, et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood. 2003;101:729\u201338.","journal-title":"Blood"},{"key":"8931_CR68","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1084\/jem.20020732","volume":"196","author":"AP Vicari","year":"2002","unstructured":"Vicari AP, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med. 2002;196:541\u20139.","journal-title":"J Exp Med"},{"key":"8931_CR69","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1158\/0008-5472.CAN-08-2499","volume":"69","author":"T Fujita","year":"2009","unstructured":"Fujita T, et al. Inhibition of transforming growth factor-\u03b2-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 2009;69:5142\u201350.","journal-title":"Cancer Res"},{"key":"8931_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1212631","volume":"94","author":"MK Callahan","year":"2013","unstructured":"Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41\u201353.","journal-title":"J Leukoc Biol"},{"key":"8931_CR71","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/2326-6066.CIR-15-0190","volume":"3","author":"R Houot","year":"2015","unstructured":"Houot R, Schultz LM, Marabelle A, Kohrt H. T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res. 2015;3:1115\u201322.","journal-title":"Cancer Immunol Res"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-017-8931-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-017-8931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-017-8931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:49:26Z","timestamp":1659095366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-017-8931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["8931"],"URL":"https:\/\/doi.org\/10.1007\/s12026-017-8931-1","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]},"assertion":[{"value":"28 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}